{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:29:35Z","timestamp":1791563375963,"version":"4.3.4"},"reference-count":330,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.cjca.2016.01.003","type":"journal-article","created":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T23:04:46Z","timestamp":1452812686000},"page":"S35-S65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":185,"special_numbering":"S","title":["Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)"],"prefix":"10.1016","volume":"32","author":[{"given":"G.B. John","family":"Mancini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fitchett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Frohlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Genest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen J.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Yashar","family":"Tashakkor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2016.01.003_bib1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cjca.2011.05.007","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus Update","volume":"29","author":"Mancini","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ahj.2007.06.008","article-title":"Distribution of creatine kinase in the general population: implications for statin therapy","volume":"154","author":"Brewster","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2016.01.003_bib4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.4103\/2230-8210.113754","article-title":"Safety of statins","volume":"17","author":"Maji","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.cjca.2016.01.003_bib5","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.amjcard.2014.02.033","article-title":"Statin intolerance","volume":"113","author":"Ahmad","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib6","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib7","doi-asserted-by":"crossref","first-page":"g3743","DOI":"10.1136\/bmj.g3743","article-title":"Non-cardiovascular effects associated with statins","volume":"349","author":"Desai","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2016.01.003_bib8","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the Statin Intolerance Panel: 2014 update","volume":"8","author":"Guyton","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2014.03.003","article-title":"NLA Task Force on Statin Safety - 2014 update","volume":"8","author":"Jacobson","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1074248414529622","article-title":"Addressing statin adverse effects in the clinic: the 5 Ms","volume":"19","author":"Katz","year":"2014","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cjca.2016.01.003_bib11","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jacl.2014.02.012","article-title":"An assessment by the Statin Diabetes Safety Task Force: 2014 update","volume":"8","author":"Maki","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib12","first-page":"497","article-title":"Statin adverse effects: sorting out the evidence","volume":"63","author":"Mlodinow","year":"2014","journal-title":"J\u00a0Fam Pract"},{"key":"10.1016\/j.cjca.2016.01.003_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2217\/clp.14.23","article-title":"Statin intolerance: diagnosis, treatment and alternative therapies","volume":"9","author":"Naderi","year":"2014","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jicc.2015.02.006","article-title":"Management of dyslipidaemia in statin-intolerant patients in light of AHA and NPA guidelines of 2013\u20132014","volume":"5","author":"Patnaik","year":"2015","journal-title":"J\u00a0Indian Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update","volume":"96","author":"Ramsey","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2016.01.003_bib16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"10","author":"Reiner","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib17","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jacl.2014.02.013","article-title":"An assessment by the Statin Cognitive Safety Task Force: 2014 update","volume":"8","author":"Rojas-Fernandez","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib18","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cjca.2016.01.003_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.cjca.2016.01.003_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11883-014-0471-8","article-title":"When compliance is an issue-how to enhance statin adherence and address adverse effects","volume":"17","author":"Birtcher","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cjca.2016.01.003_bib22","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1161\/CIRCULATIONAHA.114.013189","article-title":"Statin intolerance","volume":"131","author":"Fitchett","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.01.003_bib23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.nurpra.2014.09.004","article-title":"Statins: an update on clinical issues and selected adverse effects","volume":"11","author":"Gulum","year":"2015","journal-title":"Jpn J Nurse Pract"},{"key":"10.1016\/j.cjca.2016.01.003_bib24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/clc.22432","article-title":"Insights into statin intolerance","volume":"38","author":"Kopecky","year":"2015","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11886-015-0582-z","article-title":"Statin intolerance: diagnosis and remedies","volume":"17","author":"Pirillo","year":"2015","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.cjca.2016.01.003_bib26","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2016.01.003_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11883-015-0552-3","article-title":"Statin intolerance: the clinician's perspective","volume":"17","author":"Stulc","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cjca.2016.01.003_bib28","first-page":"17","article-title":"Statin-associated adverse events","volume":"7","author":"Yuet","year":"2015","journal-title":"Clin Med Insights Ther"},{"key":"10.1016\/j.cjca.2016.01.003_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/clpt.2014.82","article-title":"Pharmacogenomics, lipid disorders and treatment options","volume":"96","author":"Gryn","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2016.01.003_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","article-title":"Statin myotoxicity: a review of genetic susceptibility factors","volume":"24","author":"Needham","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.cjca.2016.01.003_bib31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.atherosclerosis.2015.03.025","article-title":"Genetic and immunologic susceptibility to statin-related myopathy","volume":"240","author":"Patel","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2016.01.003_bib32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature12508","article-title":"A\u00a0statin-dependent QTL for GATM expression is associated with statin-induced myopathy","volume":"502","author":"Mangravite","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2016.01.003_bib34","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature13629","article-title":"GATM locus does not replicate in rhabdomyolysis study","volume":"513","author":"Floyd","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2016.01.003_bib35","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.cmet.2015.03.003","article-title":"GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals","volume":"21","author":"Luzum","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.cjca.2016.01.003_bib36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care","volume":"6","author":"DeGorter","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.cjca.2016.01.003_bib37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ymgme.2011.07.001","article-title":"Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies","volume":"104","author":"Vladutiu","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cjca.2016.01.003_bib38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.amjmed.2014.08.031","article-title":"Bad is more powerful than good: the nocebo response in medical consultations","volume":"128","author":"Greville-Harris","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacc.2006.09.036","article-title":"Placebo and nocebo in cardiovascular health: implications for healthcare, research, and the doctor-patient relationship","volume":"49","author":"Olshansky","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib40","first-page":"459","article-title":"Nocebo phenomena in medicine: their relevance in everyday clinical practice","volume":"109","author":"H\u00e4user","year":"2012","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.cjca.2016.01.003_bib41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/0004867412464717","article-title":"The nocebo effect: a clinicians guide","volume":"47","author":"Data-Franco","year":"2013","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.cjca.2016.01.003_bib42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/postgradmedj-2012-131730","article-title":"The nocebo effect: patient expectations and medication side effects","volume":"89","author":"Faasse","year":"2013","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.cjca.2016.01.003_bib43","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/imj.12380","article-title":"Medicine's inconvenient truth: the placebo and nocebo effect","volume":"44","author":"Arnold","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.cjca.2016.01.003_bib44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jama.2014.8342","article-title":"Avoiding nocebo effects to optimize treatment outcome","volume":"312","author":"Bingel","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2016.01.003_bib45","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/2047487314525531","article-title":"What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice","volume":"21","author":"Finegold","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.euroneuro.2013.11.014","article-title":"The placebo-nocebo response: controversies and challenges from clinical and research perspective","volume":"24","author":"Jakovljevic","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.cjca.2016.01.003_bib47","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.pain.2014.04.016","article-title":"The magnitude of nocebo effects in pain: a meta-analysis","volume":"155","author":"Petersen","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.cjca.2016.01.003_bib48","doi-asserted-by":"crossref","first-page":"g5019","DOI":"10.1136\/bmj.g5019","article-title":"Unhelpful information about adverse drug reactions","volume":"349","author":"Tan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2016.01.003_bib49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jpsychores.2015.04.014","article-title":"Accentuate the positive: counteracting psychogenic responses to media health messages in the age of the Internet","volume":"79","author":"Crichton","year":"2015","journal-title":"J\u00a0Psychosom Res"},{"key":"10.1016\/j.cjca.2016.01.003_bib50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/00029157.2014.976785","article-title":"Placebo and nocebo effects: a complex interplay between psychological factors and neurochemical networks","volume":"57","author":"Frisaldi","year":"2015","journal-title":"Am J Clin Hypn"},{"key":"10.1016\/j.cjca.2016.01.003_bib51","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/jan.12637","article-title":"Nocebo and the potential harm of \u2018high risk\u2019 labelling: a scoping review","volume":"71","author":"Symon","year":"2015","journal-title":"J\u00a0Adv Nurs"},{"key":"10.1016\/j.cjca.2016.01.003_bib52","doi-asserted-by":"crossref","unstructured":"Tobert JA, Newman CB. Statin tolerability: in defence of placebo-controlled trials. Eur J Prev Cardiol 2016;23:891-6.","DOI":"10.1177\/2047487315602861"},{"key":"10.1016\/j.cjca.2016.01.003_bib53","first-page":"244","article-title":"Herbs with anti-lipid effects and their interactions with statins as a chemical anti- hyperlipidemia group drugs: a systematic review","volume":"11","author":"Rouhi-Boroujeni","year":"2015","journal-title":"ARYA Atheroscler"},{"key":"10.1016\/j.cjca.2016.01.003_bib54","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.12659\/MSM.890777","article-title":"Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study","volume":"20","author":"Skarlovnik","year":"2014","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.cjca.2016.01.003_bib55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A\u00a0randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2016.01.003_bib56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2016.01.003_bib57","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.clinthera.2014.02.023","article-title":"Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: a retrospective review","volume":"36","author":"Mergenhagen","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.cjca.2016.01.003_bib58","doi-asserted-by":"crossref","first-page":"e88877","DOI":"10.1371\/journal.pone.0088877","article-title":"Association of vitamin D and incident statin induced myalgia\u2013a retrospective cohort study","volume":"9","author":"Palamaner Subash Shantha","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2016.01.003_bib59","first-page":"42","article-title":"Low plasma vitamin D levels and muscle-related adverse effects in statin users","volume":"16","author":"Eisen","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.cjca.2016.01.003_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2008.11.002","article-title":"Low serum 25 (OH) vitamin D levels (< 32 ng\/mL) are associated with reversible myositis-myalgia in statin-treated patients","volume":"153","author":"Ahmed","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.cjca.2016.01.003_bib61","first-page":"86","article-title":"Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation","volume":"7","author":"Khayznikov","year":"2015","journal-title":"N\u00a0Am J Med Sci"},{"key":"10.1016\/j.cjca.2016.01.003_bib62","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2265.2008.03448.x","article-title":"Vitamin D insufficiency - a novel mechanism of statin-induced myalgia?","volume":"71","author":"Lee","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.cjca.2016.01.003_bib63","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2015.04.004","article-title":"Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis","volume":"240","author":"Gerards","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2016.01.003_bib64","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2015.09.032","article-title":"Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in\u00a0vitro evidence to clinical studies","volume":"243","author":"Pirillo","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2016.01.003_bib65","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.phymed.2014.11.018","article-title":"Berberis aristata\/Silybum marianum fixed combination (Berberol) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial","volume":"22","author":"Derosa","year":"2015","journal-title":"Phytomedicine"},{"key":"10.1016\/j.cjca.2016.01.003_bib66","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib67","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1161\/ATVBAHA.115.306442","article-title":"Nonstatin low-density lipoprotein-lowering therapy and cardiovascular risk reduction-statement from ATVB Council","volume":"35","author":"Hegele","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2016.01.003_bib68","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.01.003_bib69","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib70","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.01.003_bib71","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib72","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib73","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib74","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s12272-011-0813-9","article-title":"Retrospective study on antihyperlipidemic efficacy and safety of simvastatin, ezetimibe and their combination in Korean adults","volume":"34","author":"Lee","year":"2011","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.cjca.2016.01.003_bib75","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1753944713513222","article-title":"Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients","volume":"7","author":"Suzuki","year":"2013","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib76","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1517\/14740338.2015.1063613","article-title":"An observational study of ezetimibe in cardiac transplant recipients receiving calcineurin inhibitors","volume":"47","author":"Makkar","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cjca.2016.01.003_bib77","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1517\/14740338.2015.1063613","article-title":"Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?","volume":"14","author":"Husain","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cjca.2016.01.003_bib78","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jpeds.2015.02.043","article-title":"Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia","volume":"166","author":"Kusters","year":"2015","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cjca.2016.01.003_bib79","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/imj.12706","article-title":"Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis","volume":"45","author":"Luo","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.cjca.2016.01.003_bib80","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijcard.2015.08.103","article-title":"Safety and efficacy of ezetimibe: a meta-analysis","volume":"201","author":"Savarese","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib81","first-page":"1","article-title":"Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options","author":"Serban","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cjca.2016.01.003_bib82","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/clc.22441","article-title":"Effect of low-density lipoprotein cholesterol lowering by ezetimibe\/simvastatin on outcome incidence: overview, meta-analyses, and meta-regression analyses of randomized trials","volume":"38","author":"Thomopoulos","year":"2015","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib83","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib84","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.amjcard.2014.08.016","article-title":"Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial","volume":"114","author":"Green","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib85","doi-asserted-by":"crossref","first-page":"e0124587","DOI":"10.1371\/journal.pone.0124587","article-title":"Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Battaggia","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2016.01.003_bib86","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0828-282X(06)70253-7","article-title":"Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor","volume":"22","author":"Simard","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib87","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4103\/0253-7613.165178","article-title":"Myopathy induced by statinezetimibe combination: evaluation of potential risk factors","volume":"47","author":"Brahmachari","year":"2015","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.cjca.2016.01.003_bib88","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3899\/jrheum.090660","article-title":"Ezetimibe-induced relapsing polymyositis","volume":"37","author":"Garcia-Valladares","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cjca.2016.01.003_bib89","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.115.016080","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk","volume":"132","author":"Bergeron","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.01.003_bib90","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib91","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib92","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2016.01.003_bib93","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib94","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosissup.2015.02.005","article-title":"Mipomersen and lomitapide: two new drugs for the treatment of homozygous familial hypercholesterolemia","volume":"18","author":"Gouni-Berthold","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.cjca.2016.01.003_bib95","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2016.01.003_bib96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.NPR.0000443232.02852.f8","article-title":"Avoiding patient morbidity: updated statin drug interactions and risks for patient harm","volume":"39","author":"Finks","year":"2014","journal-title":"Nurse Pract"},{"key":"10.1016\/j.cjca.2016.01.003_bib97","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"A\u00a0clinician's guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib98","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eimc.2014.03.014","article-title":"Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?","volume":"32","author":"Bastida","year":"2014","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.cjca.2016.01.003_bib99","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1665-2681(19)30853-1","article-title":"Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin","volume":"13","author":"Kanter","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cjca.2016.01.003_bib100","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/imj.12464","article-title":"Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin","volume":"44","author":"Page","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.cjca.2016.01.003_bib101","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jns.2013.10.040","article-title":"Rhabdomyolysis in an elderly multitreated patient: multiple drug interactions after statin withdrawal","volume":"336","author":"Ginanneschi","year":"2014","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.cjca.2016.01.003_bib102","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/AAC.02910-14","article-title":"Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors","volume":"58","author":"Bland","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cjca.2016.01.003_bib103","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1515\/dmdi-2012-0033","article-title":"Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability","volume":"28","author":"Golightly","year":"2013","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1016\/j.cjca.2016.01.003_bib104","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1331\/JAPhA.2015.14151","article-title":"Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin","volume":"55","author":"Kido","year":"2015","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.cjca.2016.01.003_bib105","first-page":"136","article-title":"Ticagrelor-induced renal failure leading to statin-induced rhabdomyolysis","volume":"73","author":"van Vuren","year":"2015","journal-title":"Neth J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib106","doi-asserted-by":"crossref","first-page":"e69545","DOI":"10.1371\/journal.pone.0069545","article-title":"Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy\u2013a nationwide register study","volume":"8","author":"Settergren","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2016.01.003_bib107","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1503\/cmaj.140950","article-title":"Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4","volume":"187","author":"Li","year":"2015","journal-title":"CMAJ"},{"key":"10.1016\/j.cjca.2016.01.003_bib108","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jacl.2013.10.006","article-title":"Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study","volume":"8","author":"Ito","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib109","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.mayocp.2014.07.011","article-title":"Prognostic value of exercise capacity in patients with coronary artery disease: the FIT (Henry Ford ExercIse Testing) project","volume":"89","author":"Hung","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2016.01.003_bib110","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ahj.2015.04.030","article-title":"Cardiorespiratory fitness attenuates risk for major adverse cardiac events in hyperlipidemic men and women independent of statin therapy: the Henry Ford ExercIse Testing Project","volume":"170","author":"Hung","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2016.01.003_bib111","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamainternmed.2014.2266","article-title":"Statins and physical activity in older men: the osteoporotic fractures in men study","volume":"174","author":"Lee","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib112","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2015.06.047","article-title":"Impact of statin use on cardiorespiratory fitness in multi-racial men and women: the Henry Ford Exercise Testing (FIT) Project","volume":"197","author":"Qureshi","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib113","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.01.003_bib114","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.cjca.2016.01.003_bib115","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib116","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/mus.23309","article-title":"Mitochondria of trained skeletal muscle are protected from deleterious effects of statins","volume":"46","author":"Bouitbir","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cjca.2016.01.003_bib117","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.atherosclerosis.2014.12.055","article-title":"Inhibition of xanthine oxidase to prevent statin-induced myalgia and rhabdomiolysis","volume":"239","author":"Alis","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2016.01.003_bib118","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccl.2015.02.005","article-title":"Statins and the liver","volume":"33","author":"Herrick","year":"2015","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.cjca.2016.01.003_bib119","unstructured":"U.S. Department of Health and Human Services. U.S. Food and Drug Administration. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. Available at: http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm293101.htm. Accessed December 8,\u00a02015."},{"key":"10.1016\/j.cjca.2016.01.003_bib120","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.metabol.2015.07.003","article-title":"Nonalcoholic fatty liver disease and statins","volume":"64","author":"Tziomalos","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.cjca.2016.01.003_bib121","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.dld.2014.07.170","article-title":"The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease","volume":"47","author":"Pastori","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib122","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10654-013-9806-y","article-title":"Statin use and risk of hepatocellular carcinoma","volume":"28","author":"Lai","year":"2013","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib123","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/liv.12191","article-title":"Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis","volume":"33","author":"Cash","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.cjca.2016.01.003_bib124","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.27157","article-title":"Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network","volume":"60","author":"Russo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cjca.2016.01.003_bib125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4254\/wjh.v6.i4.160","article-title":"Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease","volume":"6","author":"Castiella","year":"2014","journal-title":"World J Hepatol"},{"key":"10.1016\/j.cjca.2016.01.003_bib126","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.atherosclerosis.2014.02.022","article-title":"High-potency statins increase the risk of acute kidney injury: evidence from a large population-based study","volume":"234","author":"Corrao","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2016.01.003_bib127","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/pds.3433","article-title":"Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure","volume":"22","author":"Chung","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cjca.2016.01.003_bib128","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/pds.3500","article-title":"Acute kidney injury in statin initiators","volume":"22","author":"Layton","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cjca.2016.01.003_bib129","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.amjcard.2014.05.033","article-title":"Meta-analysis of the effect of statins on renal function","volume":"114","author":"Geng","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib130","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.ijcard.2012.05.010","article-title":"Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis","volume":"167","author":"Savarese","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib131","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1253\/circj.CJ-11-1385","article-title":"Effects of rosuvastatin and atorvastatin on renal function - meta-analysis","volume":"76","author":"Wu","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.cjca.2016.01.003_bib132","doi-asserted-by":"crossref","first-page":"e0132970","DOI":"10.1371\/journal.pone.0132970","article-title":"Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis","volume":"10","author":"Sanguankeo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2016.01.003_bib133","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1517\/14740338.2015.1085504","article-title":"Do statins prevent acute kidney injury?","volume":"14","author":"Philips","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cjca.2016.01.003_bib134","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1093\/eurheartj\/ehv393","article-title":"Lowering cholesterol in chronic kidney disease: is it safe and effective?","volume":"36","author":"Wong","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2016.01.003_bib135","doi-asserted-by":"crossref","unstructured":"Schoenfeld SR, Lu L, Rai SK, et\u00a0al. Statin use and mortality in rheumatoid arthritis: a general population-based cohort study [e-pub ahead of print]. Ann Rheum Dis http:\/\/dx.doi.org\/10.1136\/annrheumdis-2015\u2013207714, accessed August 10, 2015.","DOI":"10.1136\/annrheumdis-2015-207714"},{"key":"10.1016\/j.cjca.2016.01.003_bib136","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/1756-185X.12415","article-title":"Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?","volume":"17","author":"Danninger","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib137","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/acr.22029","article-title":"Impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis versus non-rheumatoid arthritis subjects: results from a population-based study","volume":"65","author":"Myasoedova","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cjca.2016.01.003_bib138","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1097\/MD.0000000000000572","article-title":"Effect of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor on disease activity in patients with rheumatoid arthritis: a meta-analysis","volume":"94","author":"Xing","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cjca.2016.01.003_bib139","first-page":"69","article-title":"The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis","volume":"33","author":"Lv","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cjca.2016.01.003_bib140","first-page":"326258","article-title":"The role of simvastatin in the therapeutic approach of rheumatoid arthritis","volume":"2013","author":"Cojocaru","year":"2013","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib141","first-page":"3","article-title":"Association of the use of statins with disease activity and functional status in Puerto Ricans with rheumatoid arthritis","volume":"33","author":"Villafr\u00e1dez-D\u00edaz","year":"2014","journal-title":"P\u00a0R Health Sci J"},{"key":"10.1016\/j.cjca.2016.01.003_bib142","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1258\/smj.2012.012004","article-title":"Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study","volume":"57","author":"Kumar","year":"2012","journal-title":"Scott Med J"},{"key":"10.1016\/j.cjca.2016.01.003_bib143","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s10067-015-3049-0","article-title":"Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment","volume":"34","author":"Akiyama","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cjca.2016.01.003_bib144","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00011-013-0702-4","article-title":"Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis","volume":"63","author":"Pereira","year":"2014","journal-title":"Inflamm Res"},{"key":"10.1016\/j.cjca.2016.01.003_bib145","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib146","doi-asserted-by":"crossref","first-page":"689426","DOI":"10.1155\/2014\/689426","article-title":"Statins do not influence long-term rituximab clinical efficiency in rheumatoid arthritis patients","volume":"2014","author":"Mazilu","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.cjca.2016.01.003_bib147","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.amjcard.2013.04.059","article-title":"Frequency of development of connective tissue disease in statin-users versus nonusers","volume":"112","author":"Schmidt","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib148","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/annrheumdis-2013-204351","article-title":"Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in\u00a0vivo statin treatment","volume":"74","author":"Ruiz-Limon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib149","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10067-014-2654-7","article-title":"Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial","volume":"33","author":"Fatemi","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cjca.2016.01.003_bib150","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12026-013-8409-8","article-title":"Statins and autoimmunity","volume":"56","author":"Khattri","year":"2013","journal-title":"Immunol Res"},{"key":"10.1016\/j.cjca.2016.01.003_bib151","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3899\/jrheum.121150","article-title":"Statin use in giant cell arteritis: a retrospective study","volume":"40","author":"Schmidt","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cjca.2016.01.003_bib152","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/08916934.2015.1027818","article-title":"The role of statins in inflammatory vasculitides","volume":"48","author":"Tremoulet","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.cjca.2016.01.003_bib153","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/j.1756-185X.2010.01481.x","article-title":"ANCA-positive vasculitis associated with simvastatin\/ezetimibe: expanding the spectrum of statin-induced autoimmunity?","volume":"13","author":"Sen","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib154","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/rheumatology\/kev270","article-title":"High systemic levels of low-density lipoprotein cholesterol: fuel to the flames in inflammatory osteoarthritis?","volume":"55","author":"de Munter","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cjca.2016.01.003_bib155","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s11606-013-2382-8","article-title":"Statin use and clinical osteoarthritis in the general population: a longitudinal study","volume":"28","author":"Kadam","year":"2013","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib156","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/annrheumdis-2011-200092","article-title":"Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study","volume":"71","author":"Clockaerts","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib157","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0034-1375959","article-title":"Drug-induced liver injury with autoimmune features","volume":"34","author":"deLemos","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib158","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4046\/trd.2015.78.3.281","article-title":"A\u00a0case of statin-induced interstitial pneumonitis due to rosuvastatin","volume":"78","author":"Kim","year":"2015","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.cjca.2016.01.003_bib159","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/postgradmedj-2011-130209","article-title":"Statin-induced lung injury: diagnostic clue and outcome","volume":"89","author":"Huang","year":"2013","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.cjca.2016.01.003_bib160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jocn.2013.11.009","article-title":"Statins can induce myasthenia gravis","volume":"21","author":"Gale","year":"2014","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.cjca.2016.01.003_bib161","doi-asserted-by":"crossref","unstructured":"Gonen KA, Erfan G, Oznur M, Erdogan C. The first case of Henoch-Schonlein purpura associated with rosuvastatin: colonic involvement coexisting with small intestine [e-pub ahead of print]. BMJ Case Rep http:\/\/dx.doi.org\/10.1136\/bcr-2013\u2013202644, accessed March 27, 2014.","DOI":"10.1136\/bcr-2013-202644"},{"key":"10.1016\/j.cjca.2016.01.003_bib162","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/AC.70.3.3080648","article-title":"Atorvastatin-induced dermatomyositis in a 47-year-old woman with Sjogren's syndrome","volume":"70","author":"Komai","year":"2015","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib163","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jbspin.2014.03.022","article-title":"Drug-induced tendinopathy: from physiology to clinical applications","volume":"81","author":"Kirchgesner","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.cjca.2016.01.003_bib164","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/RHU.0b013e318289ddf5","article-title":"Piriformis muscle syndrome: an unusual adverse effect of atorvastatin","volume":"19","author":"Hamdi","year":"2013","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.cjca.2016.01.003_bib165","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40266-015-0302-9","article-title":"Prevalence of potential and clinically relevant statin-drug interactions in frail and robust older inpatients","volume":"32","author":"Thai","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1016\/j.cjca.2016.01.003_bib166","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacc.2007.06.063","article-title":"Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis","volume":"51","author":"Afilalo","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib167","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00228-013-1570-0","article-title":"Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis","volume":"69","author":"Yan","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2016.01.003_bib168","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11883-013-0385-x","article-title":"Treatment of cholesterol in the elderly: statins and beyond","volume":"16","author":"LaRosa","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cjca.2016.01.003_bib169","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bcp.12687","article-title":"Myopathy in older people receiving statin therapy: a systematic review and meta-analysis","volume":"80","author":"Iwere","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2016.01.003_bib170","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40266-015-0290-9","article-title":"Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis","volume":"32","author":"Teng","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1016\/j.cjca.2016.01.003_bib171","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamainternmed.2015.0289","article-title":"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial","volume":"175","author":"Kutner","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib172","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1600-0838.2011.01437.x","article-title":"No adverse effects of statins on muscle function and health-related parameters in the elderly: an exercise study","volume":"23","author":"Panayiotou","year":"2013","journal-title":"Scand J Med Sci Sports"},{"key":"10.1016\/j.cjca.2016.01.003_bib173","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jgs.12414","article-title":"Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment","volume":"61","author":"Steenland","year":"2013","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.cjca.2016.01.003_bib174","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/joim.12262","article-title":"Statin use reduces the risk of dementia in elderly patients: a nationwide data survey and propensity analysis","volume":"277","author":"Wu","year":"2015","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib175","doi-asserted-by":"crossref","first-page":"658","DOI":"10.18773\/austprescr.2013.034","article-title":"Safety profile of high-dose statin therapy in geriatric patients with stroke","volume":"106","author":"Manocha","year":"2013","journal-title":"South Med J"},{"key":"10.1016\/j.cjca.2016.01.003_bib176","doi-asserted-by":"crossref","first-page":"79","DOI":"10.18773\/austprescr.2013.034","article-title":"Statins in older adults","volume":"36","author":"Hilmer","year":"2013","journal-title":"Aust Prescr"},{"key":"10.1016\/j.cjca.2016.01.003_bib177","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/157488471003150820152249","article-title":"Statin therapy and cognition in older people: what is the evidence?","volume":"10","author":"Gnjidic","year":"2015","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.cjca.2016.01.003_bib178","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM198904063201405","article-title":"Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial","volume":"320","author":"Iso","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib179","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1212\/01.wnl.0000296277.63350.77","article-title":"Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study","volume":"70","author":"Goldstein","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.cjca.2016.01.003_bib180","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/CIRCULATIONAHA.111.055269","article-title":"Statins and intracerebral hemorrhage collaborative systematic review and meta-analysis","volume":"124","author":"Hackam","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.01.003_bib181","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.112.655894","article-title":"Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials","volume":"43","author":"McKinney","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2016.01.003_bib182","doi-asserted-by":"crossref","first-page":"e92388","DOI":"10.1371\/journal.pone.0092388","article-title":"Statins for the prevention of stroke: a meta-analysis of randomized controlled trials","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2016.01.003_bib183","doi-asserted-by":"crossref","first-page":"e007075","DOI":"10.1136\/bmjopen-2014-007075","article-title":"Statin use and risk of haemorrhagic stroke in a community-based cohort of postmenopausal women: an observational study from the Women's Health Initiative","volume":"5","author":"Salmoirago-Blotcher","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.cjca.2016.01.003_bib184","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ene.12273","article-title":"Association between statin use and intracerebral hemorrhage: a systematic review and meta-analysis","volume":"21","author":"Lei","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cjca.2016.01.003_bib185","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S1474-4422(14)70084-5","article-title":"Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial","volume":"13","author":"Kirkpatrick","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cjca.2016.01.003_bib186","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jns.2015.08.013","article-title":"Cognitive outcome in acute simvastatin treatment for aneurysmal subarachnoid hemorrhage: a propensity matched analysis","volume":"358","author":"Wong","year":"2015","journal-title":"J\u00a0Neurol Sci"},{"issue":"suppl A100","key":"10.1016\/j.cjca.2016.01.003_bib187","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ijs.12624","article-title":"Statin use in spontaneous intracerebral hemorrhage: a systematic review and meta-analysis","volume":"10","author":"Jung","year":"2015","journal-title":"Int J Stroke"},{"key":"10.1016\/j.cjca.2016.01.003_bib188","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.06.036","article-title":"Meta-analysis of statin use for the acute therapy of spontaneous intracerebral hemorrhage","volume":"24","author":"Tapia Perez","year":"2015","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib189","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.0000000000001814","article-title":"Statin treatment reduces the risk of poststroke seizures","volume":"85","author":"Guo","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.cjca.2016.01.003_bib190","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1212\/WNL.0000000000001878","article-title":"Statins for poststroke seizures: the first antiepileptogenic agent?","volume":"85","author":"Siniscalchi","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.cjca.2016.01.003_bib191","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.pjnns.2015.07.007","article-title":"Potential role of statins in the intracerebral hemorrhage and subarachnoid hemorrhage","volume":"49","author":"Kotl\u0119ga","year":"2015","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.cjca.2016.01.003_bib192","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJM200404083501524","article-title":"Central nervous system and limb anomalies in case reports of first-trimester statin exposure","volume":"350","author":"Edison","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib193","doi-asserted-by":"crossref","first-page":"h1035","DOI":"10.1136\/bmj.h1035","article-title":"Statins and congenital malformations: cohort study","volume":"350","author":"Bateman","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2016.01.003_bib194","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/11632010-000000000-00000","article-title":"Statins and pregnancy: between supposed risks and theoretical benefits","volume":"72","author":"Lecarpentier","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.cjca.2016.01.003_bib195","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/GCO.0000000000000026","article-title":"Statins in pregnancy","volume":"25","author":"Morton","year":"2013","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.cjca.2016.01.003_bib196","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/1471-0528.12066","article-title":"Pregnancy outcome following maternal exposure to statins: a multicentre prospective study","volume":"120","author":"Winterfeld","year":"2013","journal-title":"BJOG"},{"key":"10.1016\/j.cjca.2016.01.003_bib197","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1016\/j.amjmed.2013.02.032","article-title":"Rosuvastatin is transferred into human breast milk: a case report","volume":"126","author":"Schutte","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib198","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/MOL.0b013e3283587522","article-title":"Familial hypercholesterolemia in children and adolescents","volume":"23","author":"McCrindle","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib199","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.cjca.2014.09.028","article-title":"Canadian Cardiovascular Society position statement on familial hypercholesterolemia","volume":"30","author":"Genest","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib200","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2016.01.003_bib201","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11886-015-0629-1","article-title":"Optimizing treatment of familial hypercholesterolemia in children and adolescents","volume":"17","author":"Luirink","year":"2015","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.cjca.2016.01.003_bib202","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jacl.2015.06.013","article-title":"Lipid-lowering medications for children and adolescents","volume":"9","author":"Miller","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib203","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/jama.2014.8892","article-title":"Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia","volume":"312","author":"Kusters","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2016.01.003_bib204","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40272-014-0116-y","article-title":"Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence","volume":"17","author":"Braamskamp","year":"2015","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.cjca.2016.01.003_bib205","unstructured":"CardioRisk Calculator. Available at: http:\/\/www.circl.ubc.ca\/cardiorisk-calculator.html. Accessed December 8,\u00a02015."},{"key":"10.1016\/j.cjca.2016.01.003_bib206","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7326\/M13-1921","article-title":"N-of-1 (single-patient) trials for statin-related myalgia","volume":"160","author":"Joy","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib207","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib208","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2016.01.003_bib209","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A\u00a0novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cjca.2016.01.003_bib210","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1755-5922.2010.00237.x","article-title":"Statins alter intracellular calcium homeostasis in malignant hyperthermia susceptible individuals","volume":"28","author":"Metterlein","year":"2010","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cjca.2016.01.003_bib211","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2044-5040-3-22","article-title":"Mice with RyR1 mutation (Y524S) undergo hypermetabolic response to simvastatin","volume":"3","author":"Knoblauch","year":"2013","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.cjca.2016.01.003_bib212","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/art.11013","article-title":"Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility","volume":"49","author":"Guis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cjca.2016.01.003_bib213","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/art.22100","article-title":"In\u00a0vivo and in\u00a0vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects","volume":"55","author":"Guis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cjca.2016.01.003_bib214","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00228-014-1776-9","article-title":"Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives","volume":"71","author":"Hedenmalm","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.cjca.2016.01.003_bib215","first-page":"CD004760","article-title":"Creatine for treating muscle disorders","author":"Kley","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjca.2016.01.003_bib216","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1751-7141.2009.00028.x","article-title":"Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity","volume":"12","author":"Mareedu","year":"2009","journal-title":"Prev Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib217","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature13628","article-title":"GATM gene variants and statin myopathy risk","volume":"513","author":"Carr","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2016.01.003_bib218","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.nmd.2013.04.011","article-title":"Creatine deficiency syndrome. A treatable myopathy due to arginine-glycine amidinotransferase (AGAT) deficiency","volume":"23","author":"Nouioua","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.cjca.2016.01.003_bib219","doi-asserted-by":"crossref","first-page":"472","DOI":"10.5694\/j.1326-5377.2004.tb06030.x","article-title":"Successful reintroduction of statin therapy after myositis: was there another cause?","volume":"180","author":"Rando","year":"2004","journal-title":"Med J Aust"},{"key":"10.1016\/j.cjca.2016.01.003_bib220","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2015.03.005","article-title":"Successful reintroduction of statin therapy after statin-associated rhabdomyolysis","volume":"9","author":"Simons","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib221","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","article-title":"Statin-induced myopathy is associated with mitochondrial complex III inhibition","volume":"22","author":"Schirris","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.cjca.2016.01.003_bib222","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/jcb.24077","article-title":"3-Hydroxy 3-methylglutaryl coenzyme A reductase inhibition impairs muscle regeneration","volume":"113","author":"Trapani","year":"2012","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.cjca.2016.01.003_bib223","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/stem.2107","article-title":"Cytostatic effect of repeated exposure to simvastatin: a mechanism for chronic myotoxicity revealed by the use of mesodermal progenitors derived from human pluripotent stem cells","volume":"33","author":"Peric","year":"2015","journal-title":"Stem Cells"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2016.01.003_bib224","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0140-6736(15)60336-1","article-title":"Pleiotropic effects of statins in hypercholesterolaemia: a prospective observational study using a lipoproteomic based approach","volume":"385","author":"Bhandari","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.01.003_bib225","doi-asserted-by":"crossref","first-page":"e58833","DOI":"10.1371\/journal.pone.0058833","article-title":"Cholesterol biosynthesis and homeostasis in regulation of the cell cycle","volume":"8","author":"Singh","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2016.01.003_bib226","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.bbamcr.2015.03.006","article-title":"Reductive stress impairs myoblasts mitochondrial function and triggers mitochondrial hormesis","volume":"1853","author":"Singh","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cjca.2016.01.003_bib227","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(05)61628-5","article-title":"Polymyositis associated with simvastatin","volume":"349","author":"Giordano","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.01.003_bib228","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9343(01)00711-2","article-title":"Atorvastatin-induced dermatomyositis","volume":"110","author":"Noel","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib229","series-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003","first-page":"337","volume":"14","author":"Hoogendijk","year":"2004"},{"key":"10.1016\/j.cjca.2016.01.003_bib230","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00131402-200206000-00002","article-title":"Myopathy associated with HMG-CoA reductase inhibitors (statins): a series of 10 patients and review of the literature","volume":"3","author":"McKelvie","year":"2002","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib231","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cjca.2016.01.003_bib232","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cjca.2016.01.003_bib233","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cjca.2016.01.003_bib234","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cjca.2016.01.003_bib235","doi-asserted-by":"crossref","unstructured":"Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy [e-pub ahead of print]. Clin Rev Allergy Immunol http:\/\/dx.doi.org\/10.1007\/s12016-015-8510-y, accessed October 2, 2015.","DOI":"10.1007\/s12016-015-8510-y"},{"key":"10.1016\/j.cjca.2016.01.003_bib236","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.23854","article-title":"Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies","volume":"48","author":"Mohassel","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cjca.2016.01.003_bib237","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cjca.2016.01.003_bib238","doi-asserted-by":"crossref","unstructured":"Kassardjian CD, Lennon VA, Alfugham NB, Mahler M, Milone M. Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy. JAMA Neurol 2015;72:996-1003.","DOI":"10.1001\/jamaneurol.2015.1207"},{"key":"10.1016\/j.cjca.2016.01.003_bib239","doi-asserted-by":"crossref","unstructured":"Watanabe Y, Suzuki S, Nishimura H, et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore)2015;94:e416.","DOI":"10.1097\/MD.0000000000000416"},{"key":"10.1016\/j.cjca.2016.01.003_bib240","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/rheumatology\/kev229","article-title":"Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience","volume":"54","author":"Klein","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cjca.2016.01.003_bib241","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10067-015-2935-9","article-title":"Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis\/dermatomyositis","volume":"34","author":"Chen","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cjca.2016.01.003_bib242","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1017\/cjn.2014.22","article-title":"Statin-associated autoimmune myopathies: a pathophysiologic spectrum","volume":"41","author":"Wu","year":"2014","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.cjca.2016.01.003_bib243","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3949\/ccjm.81a.13158","article-title":"Identifying statin-associated autoimmune necrotizing myopathy","volume":"81","author":"Albayda","year":"2014","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib244","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cjca.2016.01.003_bib245","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jbspin.2013.06.008","article-title":"Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins","volume":"81","author":"Lahaye","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.cjca.2016.01.003_bib246","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3109\/14397595.2013.874739","article-title":"Statin-associated necrotizing autoimmune myopathy","volume":"24","author":"Fernandes","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cjca.2016.01.003_bib247","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/BOR.0b013e328358bd85","article-title":"Myositis autoantibodies","volume":"24","author":"Casciola-Rosen","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cjca.2016.01.003_bib248","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-012-1986-4","article-title":"Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey","volume":"31","author":"Charles-Schoeman","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cjca.2016.01.003_bib249","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10072-011-0657-6","article-title":"Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis","volume":"32","author":"Sancricca","year":"2011","journal-title":"Neurol Sci"},{"key":"10.1016\/j.cjca.2016.01.003_bib250","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/ene.12174","article-title":"EFNS review on the role of muscle biopsy in the investigation of myalgia","volume":"20","author":"Kyriakides","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cjca.2016.01.003_bib251","doi-asserted-by":"crossref","first-page":"e115755","DOI":"10.1371\/journal.pone.0115755","article-title":"Statin use and cognitive function: population-based observational study with long-term follow-up","volume":"9","author":"Joosten","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2016.01.003_bib252","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40266-015-0295-4","article-title":"Use of statins and risk of dementia in heart failure: a retrospective cohort study","volume":"32","author":"Chitnis","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1016\/j.cjca.2016.01.003_bib253","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4066\/AMJ.2015.2014","article-title":"Statins and memory loss: an Australian experience","volume":"8","author":"Jamolowicz","year":"2015","journal-title":"Australas Med J"},{"key":"10.1016\/j.cjca.2016.01.003_bib254","doi-asserted-by":"crossref","first-page":"e88434","DOI":"10.1371\/journal.pone.0088434","article-title":"Effects of statins on incident dementia in patients with type 2 DM: a population-based retrospective cohort study in Taiwan","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2016.01.003_bib255","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.atherosclerosis.2013.07.009","article-title":"Long-term use of statins reduces the risk of hospitalization for dementia","volume":"230","author":"Corrao","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2016.01.003_bib256","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1161\/CIRCULATIONAHA.113.002236","article-title":"Long-term effects of secondary prevention on cognitive function in stroke patients","volume":"128","author":"Douiri","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.01.003_bib257","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/pds.3381","article-title":"Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding","volume":"22","author":"Wong","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cjca.2016.01.003_bib258","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0891988714522702","article-title":"Long-term statin use and dementia risk in Taiwan","volume":"27","author":"Chen","year":"2014","journal-title":"J\u00a0Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.cjca.2016.01.003_bib259","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijcard.2014.03.018","article-title":"Statin use and incident dementia: a nationwide cohort study of Taiwan","volume":"173","author":"Chou","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib260","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/ene.12402","article-title":"Decreased prevalence of dementia associated with statins: a national population-based study","volume":"22","author":"Chuang","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cjca.2016.01.003_bib261","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2015.05.159","article-title":"Statins and the risk of dementia in patients with atrial fibrillation: a nationwide population-based cohort study","volume":"196","author":"Chao","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib262","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jalz.2014.11.003","article-title":"Statins and brain integrity in older adults: secondary analysis of the Health ABC study","volume":"11","author":"Nadkarni","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.cjca.2016.01.003_bib263","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s13311-014-0270-5","article-title":"Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confluent white matter hyperintensities","volume":"11","author":"Xiong","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.cjca.2016.01.003_bib264","doi-asserted-by":"crossref","first-page":"e0137914","DOI":"10.1371\/journal.pone.0137914","article-title":"Statins reduces the risk of dementia in patients with late-onset depression: a retrospective cohort study","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.cjca.2016.01.003_bib265","first-page":"CD007514","article-title":"Statins for the treatment of dementia","author":"McGuinness","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjca.2016.01.003_bib266","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","article-title":"Statins and cognitive function: a systematic review","volume":"159","author":"Richardson","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib267","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2013.07.013","article-title":"Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects","volume":"88","author":"Swiger","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2016.01.003_bib268","doi-asserted-by":"crossref","first-page":"345","DOI":"10.18865\/ed.25.3.345","article-title":"Statin use, incident dementia and Alzheimer disease in elderly African Americans","volume":"25","author":"Hendrie","year":"2015","journal-title":"Ethn Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib269","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000382128","article-title":"Statins for treating Alzheimer's disease: truly ineffective?","volume":"73","author":"Liang","year":"2015","journal-title":"Eur Neurol"},{"key":"10.1016\/j.cjca.2016.01.003_bib270","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","article-title":"Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Ott","year":"2015","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib271","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrneurol.2015.35","article-title":"Statins, cognition, and dementia-systematic review and methodological commentary","volume":"11","author":"Power","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.cjca.2016.01.003_bib272","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3233\/JAD-2012-120064","article-title":"Lipid lowering agents, cognitive decline, and dementia: the Three-City Study","volume":"30","author":"Ancelin","year":"2012","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib273","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/jamainternmed.2015.2092","article-title":"Statin therapy and risk of acute memory impairment","volume":"175","author":"Strom","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib274","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ejim.2015.08.012","article-title":"Do statins prevent Alzheimer's disease? A narrative review","volume":"26","author":"Daneschvar","year":"2015","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib275","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40264-015-0339-z","article-title":"Ben Salem C. Drug-induced hyperglycaemia and diabetes","volume":"38","author":"Fathallah","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.cjca.2016.01.003_bib276","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.01.003_bib277","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2016.01.003_bib278","doi-asserted-by":"crossref","first-page":"e71817","DOI":"10.1371\/journal.pone.0071817","article-title":"Differential impact of statin on new-onset diabetes in different age groups: a population-based case-control study in women from an asian country","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2016.01.003_bib279","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.2337\/dc12-1756","article-title":"Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival","volume":"36","author":"Danaei","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2016.01.003_bib280","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.01.003_bib281","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2012.09.042","article-title":"Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy effect of baseline risk factors for diabetes","volume":"61","author":"Waters","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib282","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijcard.2015.07.107","article-title":"Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: the SAFEHEART study","volume":"201","author":"Fuentes","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib283","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jacc.2014.10.053","article-title":"Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL","volume":"65","author":"Kohli","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib284","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s11606-015-3335-1","article-title":"Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults","volume":"30","author":"Mansi","year":"2015","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib285","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.01.003_bib286","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1007\/s00125-014-3374-x","article-title":"Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis","volume":"57","author":"Erqou","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.cjca.2016.01.003_bib287","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.cjca.2015.06.010","article-title":"Incident diabetes with statins: biology, artifact, or both?","volume":"31","author":"Brahm","year":"2015","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib288","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10557-014-6546-5","article-title":"PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins","volume":"28","author":"Birnbaum","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cjca.2016.01.003_bib289","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s00125-014-3409-3","article-title":"A\u00a0dysglycaemic effect of statins in diabetes: relevance to clinical practice?","volume":"57","author":"Swerdlow","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.cjca.2016.01.003_bib290","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2016.01.003_bib291","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0140-6736(14)61639-1","article-title":"Statins and type 2 diabetes: genetic studies on target","volume":"385","author":"Frayling","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.01.003_bib292","doi-asserted-by":"crossref","first-page":"14076","DOI":"10.1038\/srep14076","article-title":"Statin-activated nuclear receptor PXR promotes SGK2 dephosphorylation by scaffolding PP2C to induce hepatic gluconeogenesis","volume":"5","author":"Gotoh","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjca.2016.01.003_bib293","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1080\/15548627.2015.1091139","article-title":"Chronic HMGCR\/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction","volume":"11","author":"Wang","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.cjca.2016.01.003_bib294","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.amjcard.2013.10.043","article-title":"Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy","volume":"113","author":"Wang","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib295","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.numecd.2014.02.012","article-title":"Putting the diabetes risk due to statins in perspective: a re-evaluation using the complementary outcome","volume":"24","author":"Furuya-Kanamori","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib296","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1590\/1806-9282.61.04.375","article-title":"Use of statins and the incidence of type 2 diabetes mellitus","volume":"61","author":"Bernardi","year":"2015","journal-title":"Rev Assoc Med Bras"},{"key":"10.1016\/j.cjca.2016.01.003_bib297","doi-asserted-by":"crossref","unstructured":"Fernandes R, Shaikh I, Wegstapel H. Possible association between statin use and bowel dysmotility. BMJ Case Rep 2012: bcr1020114918.","DOI":"10.1136\/bcr.10.2011.4918"},{"key":"10.1016\/j.cjca.2016.01.003_bib298","first-page":"199","article-title":"The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in gastrointestinal tract disorders: a comprehensive review","volume":"22","author":"Cortes-Bergoderi","year":"2013","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"key":"10.1016\/j.cjca.2016.01.003_bib299","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1507\/endocrj.K04-144","article-title":"HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism","volume":"53","author":"Tokinaga","year":"2006","journal-title":"Endocr J"},{"key":"10.1016\/j.cjca.2016.01.003_bib300","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/0972-2327.157251","article-title":"Statin-induced bilateral foot drop in a case of hypothyroidism","volume":"18","author":"Chaudhary","year":"2015","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.cjca.2016.01.003_bib301","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jacl.2014.05.005","article-title":"Hypothyroidism as a risk factor for statin intolerance","volume":"8","author":"Robison","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.01.003_bib302","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijcard.2006.07.233","article-title":"Simvastatin induced rhabdomyolysis and an important clinical link with hypothyroidism","volume":"119","author":"Kiernan","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib303","doi-asserted-by":"crossref","first-page":"547","DOI":"10.7326\/0003-4819-143-7-200510040-00025","article-title":"Interaction between simvastatin and L-thyroxine","volume":"143","author":"Kisch","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib304","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/cen.12570","article-title":"Statin use and thyroid cancer: a population-based case-control study","volume":"83","author":"Hung","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.cjca.2016.01.003_bib305","first-page":"395","article-title":"Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems","volume":"178","author":"Parsons","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.cjca.2016.01.003_bib306","first-page":"2517","article-title":"Y-27632 a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells","volume":"170","author":"Rees","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.cjca.2016.01.003_bib307","doi-asserted-by":"crossref","first-page":"L1323","DOI":"10.1152\/ajplung.00447.2003","article-title":"Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism","volume":"287","author":"Watts","year":"2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib308","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1210\/jcem.82.5.3960","article-title":"Lovastatin-induced apoptosis in prostate stromal cells","volume":"82","author":"Padayatty","year":"1997","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.cjca.2016.01.003_bib309","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1158\/1535-7163.MCT-06-0175","article-title":"Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells","volume":"5","author":"Sivaprasad","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cjca.2016.01.003_bib310","doi-asserted-by":"crossref","first-page":"750","DOI":"10.4111\/kju.2013.54.11.750","article-title":"Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia","volume":"54","author":"Lee","year":"2013","journal-title":"Korean J Urol"},{"key":"10.1016\/j.cjca.2016.01.003_bib311","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/aje\/kwt055","article-title":"A\u00a0prospective study of statin drug use and lower urinary tract symptoms in older men","volume":"178","author":"Mondul","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib312","doi-asserted-by":"crossref","first-page":"762","DOI":"10.5414\/CP202113","article-title":"Association of statin use with storage lower urinary tract symptoms (LUTS): data mining of prescription database","volume":"52","author":"Fujimoto","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2016.01.003_bib313","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5414\/CP202033","article-title":"Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS","volume":"52","author":"Fujimoto","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2016.01.003_bib314","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000431185","article-title":"Statin use is associated with bladder pain syndrome\/interstitial cystitis: a population-based case-control study","volume":"95","author":"Huang","year":"2015","journal-title":"Urol Int"},{"key":"10.1016\/j.cjca.2016.01.003_bib315","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2016.01.003_bib316","first-page":"83","article-title":"The association of statin use and gonado-sexual function in women: a retrospective cohort analysis","volume":"12","author":"Ali","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib317","first-page":"158","article-title":"Statins and male sexual health: a retrospective cohort analysis","volume":"12","author":"Davis","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib318","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ijcard.2015.10.012","article-title":"Statin use and incident erectile dysfunction - a nationwide propensity-matched cohort study in Taiwan","volume":"202","author":"Chou","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib319","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1053\/meta.2000.7716a","article-title":"Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia","volume":"49","author":"Dobs","year":"2000","journal-title":"Metabolism"},{"key":"10.1016\/j.cjca.2016.01.003_bib320","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4103\/1008-682X.123678","article-title":"The role of statins in erectile dysfunction: a systematic review and meta-analysis","volume":"16","author":"Cai","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.cjca.2016.01.003_bib321","first-page":"1367","article-title":"The effect of statins on erectile dysfunction: a systematic review and meta-analysis","volume":"11","author":"Cui","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib322","first-page":"1626","article-title":"The effect of statins on erectile dysfunction: a meta-analysis of randomized trials","volume":"11","author":"Kostis","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib323","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/ijir.2012.46","article-title":"Atorvastatin improves erectile dysfunction in patients initially irresponsive to Sildenafil by the activation of endothelial nitric oxide synthase","volume":"25","author":"El-Sisi","year":"2013","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.cjca.2016.01.003_bib324","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2490-14-24","article-title":"Simvastatin improves the sexual health-related quality of life in men aged 40 years and over with erectile dysfunction: additional data from the erectile dysfunction and statin trial","volume":"14","author":"Trivedi","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.cjca.2016.01.003_bib325","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.cjca.2014.08.020","article-title":"Statin use and risk for cataract: a nested case-control study of 2 populations in Canada and the United States","volume":"30","author":"Wise","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2016.01.003_bib326","doi-asserted-by":"crossref","first-page":"e111268","DOI":"10.1371\/journal.pone.0111268","article-title":"Herpes zoster is associated with prior statin use: a population-based case-control study","volume":"9","author":"Chung","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2016.01.003_bib327","first-page":"657","article-title":"Eruption of palmoplantar pustular psoriasis in patient treated with anti-androgen therapy for prostate cancer and aggravation of lesions after statin treatment","volume":"9","author":"Pietrzak","year":"2014","journal-title":"Cent Eur J Med"},{"key":"10.1016\/j.cjca.2016.01.003_bib328","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/DDDT.S66666","article-title":"Pemphigus erythematosus relapse associated with atorvastatin intake","volume":"8","author":"Lo Schiavo","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.cjca.2016.01.003_bib329","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/thoraxjnl-2012-201823","article-title":"Statins and the risk of interstitial lung disease: a cohort study","volume":"68","author":"Saad","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.cjca.2016.01.003_bib330","doi-asserted-by":"crossref","first-page":"e0140571","DOI":"10.1371\/journal.pone.0140571","article-title":"Statin use is associated with reduced mortality in patients with interstitial lung disease","volume":"10","author":"Vedel-Krogh","year":"2015","journal-title":"PLoS One"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X16000076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X16000076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T04:11:43Z","timestamp":1748751103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X16000076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":330,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0828282X16000076"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2016.01.003","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2016.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}